Get started
Puma Biotechnology IncPuma Biotechnology IncPuma Biotechnology Inc

Puma Biotechnology Inc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PBYI chart


Full chart

PBYI upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪139.41 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
5.98
Basic EPS (TTM)
0.48 USD
Net income (FY)
‪21.59 M‬ USD
Revenue (FY)
‪235.64 M‬ USD
Shares float
‪34.85 M‬
Beta (1Y)
−0.16

Employees


Employees (FY)
185
Change (1Y)
−7 −3.65%
Revenue / Employee (1Y)
‪1.27 M‬ USD
Net income / Employee (1Y)
‪116.71 K‬ USD

About Puma Biotechnology Inc


Sector
Health Technology
CEO
Alan H. Auerbach
Headquarters
Los Angeles
Website
pumabiotechnology.com
Founded
2010
FIGI
BBG0018YXYX7
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

PBYI news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PBYI is 3.00 USD — it has increased by 2.11% in the past 24 hours. Watch Puma Biotechnology Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Puma Biotechnology Inc stocks are traded under the ticker PBYI.
PBYI stock has fallen by −3.01% compared to the previous week, the month change is a 3.20% rise, over the last year Puma Biotechnology Inc has showed a −22.08% decrease.
We've gathered analysts' opinions on Puma Biotechnology Inc future price: according to them, PBYI price has a max estimate of 7.00 USD and a min estimate of 2.00 USD. Watch PBYI chart and read a more detailed Puma Biotechnology Inc stock forecast: see what analysts think of Puma Biotechnology Inc and suggest that you do with its stocks.
PBYI reached its all-time high on Aug 26, 2014 with the price of 279.37 USD, and its all-time low was 1.60 USD and was reached on May 11, 2022. View more price dynamics on PBYI chart.
See other stocks reaching their highest and lowest prices.
PBYI stock is 8.78% volatile and has beta coefficient of −0.16. Track Puma Biotechnology Inc stock price on the chart and check out the list of the most volatile stocks — is Puma Biotechnology Inc there?
Today Puma Biotechnology Inc has the market capitalization of ‪142.35 M‬, it has increased by 19.83% over the last week.
Yes, you can track Puma Biotechnology Inc financials in yearly and quarterly reports right on TradingView.
Puma Biotechnology Inc is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
PBYI earnings for the last quarter are 0.41 USD per share, whereas the estimation was 0.33 USD resulting in a 23.00% surprise. The estimated earnings for the next quarter are 0.09 USD per share. See more details about Puma Biotechnology Inc earnings.
Puma Biotechnology Inc revenue for the last quarter amounts to ‪80.50 M‬ USD, despite the estimated figure of ‪70.65 M‬ USD. In the next quarter, revenue is expected to reach ‪52.50 M‬ USD.
PBYI net income for the last quarter is ‪20.32 M‬ USD, while the quarter before that showed ‪−4.53 M‬ USD of net income which accounts for 548.60% change. Track more Puma Biotechnology Inc financial stats to get the full picture.
No, PBYI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 185.00 employees. See our rating of the largest employees — is Puma Biotechnology Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Puma Biotechnology Inc EBITDA is ‪43.97 M‬ USD, and current EBITDA margin is 19.01%. See more stats in Puma Biotechnology Inc financial statements.
Like other stocks, PBYI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Puma Biotechnology Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Puma Biotechnology Inc technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Puma Biotechnology Inc stock shows the sell signal. See more of Puma Biotechnology Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.